N/A
N=5
Infrared and Broadband Light for Skin Aging
Aging
Bottom Line
View on ClinicalTrials.gov: NCT03243981 ↗Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Oct 2019
Primary outcome: Primary: Number of Genes With Significant Change in Gene Transcription — 188; 45 genes
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Sciton SkinTyte (800-1800 nm) with Broadband Light Technology (Device)
- Age
- Adult, Older Adult · 55+ yrs
- Sex
- Female
- Sponsor
- Stanford University
- Primary completion
- Jun 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Genes With Significant Change in Gene Transcription |
188; 45 | — |
| SECONDARY Change From Baseline in Fine Wrinkling Score as a Measure of Skin Rejuvenation |
7.8; 7.5; 5.0; 5.3 | — |
| SECONDARY Change From Baseline in Coarse Wrinkling Score as a Measure of Skin Rejuvenation |
5.0; 6.0; 2.3; 2.5 | — |
| SECONDARY Change From Baseline in Sagging Score as a Measure of Skin Rejuvenation |
7.0; 7.5; 3.5; 4.3 | — |
| SECONDARY Change From Baseline in Physician Global Assessment as a Measure of Skin Rejuvenation |
8.3; 8.3; 5.5; 6.0 | — |
| SECONDARY Change From Baseline in Cutometry as a Measure of Skin Rejuvenation |
— | — |
| SECONDARY Change From Baseline in Transepidermal Water Loss as a Measure of Skin Rejuvenation |
— | — |
Summary
In this exploratory study, we hope to learn if treatment of broadband light with infrared light can alter the molecular pathways associated with aging. Secondary exploratory objective is to see if there are any visible effects of this light treatment on human skin.
Eligibility Criteria
Inclusion Criteria
- 1. Female 2. Age 55 years or older (total 6) 3. Fitzpatrick skin type 2-3 4. Photo-aging at least moderate on the extensor forearms
Exclusion Criteria
- 1. Unable to understand and sign informed consent form 2. Unable to comply with study procedures 3. Pregnant or lactating 4. Prior treatment to forearms including topical retinoid, laser treatment, photodynamic treatment, prescription topical agents x 1 month 5. Active skin conditions that precluding treatment including zoster, blistering skin disease, psoriasis, atopic dermatitis, abnormal scarring, skin cancer in the area of study treatment 6. Currently on hormone based therapy (both systemic and topical)
Data sourced from ClinicalTrials.gov (NCT03243981). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.